BizToc

[ad_1]

Independent advisers to the Food and Drug Administration unanimously agreed Friday that a new Alzheimer’s disease drug, Leqembi, benefits patients, all but ensuring the medication will be the first of its class to get full approval for the memory-robbing illness. The 6-0 vote confirming the…

#leqembi #fda #medicare #centersformedicare #medicaidservices #elililly #eisai #cms